Metastatic prognostic ability of lung cancer stromal cells from a single-cell RNA-seq perspective
02:17 Share

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.10.548323v1?rss=1

Authors: Moon, H., Kim, J., Jeon, H., Yang, J. O.

Abstract: Single-cell RNA sequencing (scRNA-seq) has been widely studied and analyzed to understand cancer heterogeneity. Metastasis and invasion through communication with immune cells have been widely studied; stromal cells are known to change during cancer progression and cause metastasis, but little is known about their inherent metastasis prognostic abilities. This study investigated the abilities of stromal cells by analyzing the scRNA-seq data of adjacent, tumor, and metastasized tissues, biopsied from 15 patients. We considered fibroblast and smooth muscle cells as cell subtypes of stromal cells. We detected decorin (DCN) and insulin-like growth factor-binding protein 7 (IGFBP7) as sub-cell type markers conserved in tumor and metastasis. We found an organic relationship that affects metastasis by assessing the interaction between the expression and related pathways among the assigned stromal cell subtypes. In addition to the interactions of sub-cell-types within stromal cells, we also studied communication between stromal cells and the five assigned lung cancer cell types, and observed its relation with migration and metastasis; the role of DCN as a mediating factor was also studied. Results of our study indicated that DCN and IGFBP7 are factors that can be monitored in the follow-up of prognostic metastasis factors in patients with lung cancer. Therefore, DCN and IGFBP7, which are the assigned sub-cell types marker in lung cancer stromal cells, can be used as potential biomarkers for follow-up in lung cancer metastasis. Our study assigned stromal cell subtypes of lung cancer and detected markers that can be used as monitoring factors during metastasis of lung cancer. This suggests that DCN and IGFBP7 are potential biomarkers to evaluate metastatic ability and follow-up as metastatic prognostic factors in lung cancer patients.

Copy rights belong to original authors. Visit the link for more info

Podcast created by Paper Player, LLC